Former President Donald Trump and Vice President Kamala Harris, despite their political differences, share a common ground: the need for government intervention to reduce soaring drug prices in the United States. Harris, a strong advocate for drug price regulation, played a crucial role in passing legislation allowing Medicare to negotiate drug prices for its 60 million beneficiaries. Trump, while having proposed similar measures during his first term, faced resistance in implementing them. The pharmaceutical industry, previously enjoying a seemingly untouchable status, is now facing pressure from both sides of the aisle. The election’s outcome could have a significant impact on the industry’s future, as it navigates this new era of scrutiny and potential regulatory changes.
Leave a comment
Leave a comment